The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs)

Clinical Genitourinary Cancer

Volumn 14, Issue 5, 2016, Pages 398-405

  Alashkham, Abduelmenem ^a   Paterson, Catherine ^a   Windsor, Phyllis ^b   Struthers, Allan ^a   Rauchhaus, Petra ^a   Nabi, Ghulam ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Biochemical recurrence; Hormonal therapy; Prostate cancer; Radiotherapy; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; PROSTATE CANCER; RISK REDUCTION; EPIDEMIOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; HYPERTENSION; INCIDENCE; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPENSITY SCORE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961879934     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.03.009     Document Type: Article

References (36)

1. 1 Atlas, S.A., The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13:8 Suppl B (2007), 9–20.
2. 2 Arrieta, O., Guevara, P., Escobar, E., Garcia-Navarrete, R., Pineda, B., Sotelo, J., Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92 (2005), 1247–1252.
3. 3 Greco, S., Muscella, A., Elia, M.G., et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196 (2003), 370–377.
4. 4 Takeda, H., Kondo, S., Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158 (2001), 1633–1637.
5. 5 Rocken, C., Lendeckel, U., Dierkes, J., et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 11 (2005), 2526–2530.
6. 6 Verhoest, G., Dolley-Hitze, T., Jouan, F., et al. Renin-angiotensin system and urological cancers. Prog Urol 24 (2014), 73–79.
7. 7 Dinh, D.T., Frauman, A.G., Somers, G.R., et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 196 (2002), 213–219.
8. 8 Cardwell, C.R., McMenamin, U.C., Hicks, B.M., Hughes, C., Cantwell, M.M., Murray, L.J., Drugs affecting the renin-angiotensin system and survival from cancer: a population-based study of breast, colorectal and prostate cancer patient cohorts. BMC Med, 12, 2014, 28.
9. 9 Azoulay, L., Assimes, T.L., Yin, H., Bartels, D.B., Schiffrin, E.L., Suissa, S., Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One, 7, 2012, e50893.
10. 10 Bhaskaran, K., Douglas, I., Evans, S., van Staa, T., Smeeth, L., Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ, 344, 2012, e2697.
11. 11 Chiang, Y.Y., Chen, K.B., Tsai, T.H., Tsai, W.C., Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study. J Clin Hypertens 16 (2014), 27–33.
12. 12 Ronquist, G., Frithz, G., Wang, Y.H., Lindeborg, T., Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol 43 (2009), 32–36.
13. 13 Ganeswaran, D., Sweeney, C., Yousif, F., Lang, S., Goodman, C., Nabi, G., Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol 32 (2014), 309–315.
14. 14 Guidelines on prostate cancer, 2015, European Association of Urology, 1–156 Available at: https://uroweb.org/guideline/prostate-cancer/ Accessed: March 29, 2016.
15. 15 Thoemmes F. Propensity Score Matching in SPSS. Available at: http://arxiv.org/abs/1201.6385. Accessed: September 18, 2012.
16. 16 Radiotherapy dose-fractionation, 2006, The Royal College of Radiologists, London, 1–156.
17. 17 Rodriguez, C., Jacobs, E.J., Deka, A., et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 20 (2009), 671–679.
18. 18 Asmar, R., Beebe-Dimmer, J.L., Korgavkar, K., Keele, G.R., Cooney, K.A., Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16 (2013), 62–66.
19. 19 Stuart, E.A., Rubin, D.B., Matching with multiple control groups and adjusting for group differences. J Educ Behav Stat 33 (2008), 279–306.
20. 20 Cookson, M.S., Aus, G., Burnett, A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007), 540–545.
21. 21 Ohwaki, K., Endo, F., Hattori, K., Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Cancer 51 (2015), 604–609.
22. 22 Allott, E.H., Masko, E.M., Freedland, S.J., Obesity and prostate cancer: weighing the evidence. Eur Urol 63 (2013), 800–809.
23. 23 Freedland, S.J., Aronson, W.J., Kane, C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004), 446–453.
24. 24 Allott, E.H., Howard, L.E., Cooperberg, M.R., et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 23 (2014), 2349–2356.
25. 25 Wedlake, L.J., Silia, F., Benton, B., et al. Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur J Cancer 48 (2012), 2117–2124.
26. 26 Kollmeier, M.A., Katz, M.S., Mak, K., et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 79 (2011), 713–718.
27. 27 Bolla, M., Collette, L., Blank, L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002), 103–106.
28. 28 Kaddour-Djebbar, I., Lakshmikanthan, V., Shirley, R.B., Ma, Y., Lewis, R.W., Kumar, M.V., Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol Cancer Ther 5 (2006), 1958–1966.
29. 29 Kyprianou, N., Litvak, J.P., Borkowski, A., Alexander, R., Jacobs, S.C., Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159 (1998), 1810–1815.
30. 30 Escobar, E., Rodriguez-Reyna, T.S., Arrieta, O., Sotelo, J., Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2 (2004), 385–399.
31. 31 Lindberg, H., Nielsen, D., Jensen, B.V., Eriksen, J., Skovsgaard, T., Angiotensin-converting enzyme inhibitors for cancer treatment?. Acta Oncologica 43 (2004), 142–152.
32. 32 Yoshiji, H., Kuriyama, S., Noguchi, R., Fukui, H., Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 4 (2004), 555–567.
33. 33 Uemura, H., Hoshino, K., Kubota, Y., Engagement of renin-angiotensin system in prostate cancer. Curr Cancer Drug Targets 11 (2011), 442–450.
34. 34 McKay, R.R., Rodriguez, G.E., Lin, X., et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21 (2015), 2471–2479.
35. 35 Keizman, D., Huang, P., Eisenberger, M.A., et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 47 (2011), 1955–1961.
36. 36 Krassnigg, F., Niederhauser, H., Fink, E., Frick, J., Schill, W.B., Angiotensin converting enzyme in human seminal plasma is synthesized by the testis, epididymis and prostate. Int J Androl 12 (1989), 22–28.